These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24117597)

  • 1. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).
    Bolli GB; Munteanu M; Dotsenko S; Niemoeller E; Boka G; Wu Y; Hanefeld M
    Diabet Med; 2014 Feb; 31(2):176-84. PubMed ID: 24117597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
    Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
    Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
    Ahrén B; Leguizamo Dimas A; Miossec P; Saubadu S; Aronson R
    Diabetes Care; 2013 Sep; 36(9):2543-50. PubMed ID: 23536584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
    Seino Y; Min KW; Niemoeller E; Takami A;
    Diabetes Obes Metab; 2012 Oct; 14(10):910-7. PubMed ID: 22564709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
    Fonseca VA; Alvarado-Ruiz R; Raccah D; Boka G; Miossec P; Gerich JE;
    Diabetes Care; 2012 Jun; 35(6):1225-31. PubMed ID: 22432104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.
    Ratner RE; Rosenstock J; Boka G;
    Diabet Med; 2010 Sep; 27(9):1024-32. PubMed ID: 20722676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).
    Rosenstock J; Raccah D; Korányi L; Maffei L; Boka G; Miossec P; Gerich JE
    Diabetes Care; 2013 Oct; 36(10):2945-51. PubMed ID: 23698396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
    Broglio F; Mannucci E; Napoli R; Nicolucci A; Purrello F; Nikonova E; Stager W; Trevisan R
    Diabetes Obes Metab; 2017 Feb; 19(2):248-256. PubMed ID: 27762096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
    Kapitza C; Forst T; Coester HV; Poitiers F; Ruus P; Hincelin-Méry A
    Diabetes Obes Metab; 2013 Jul; 15(7):642-9. PubMed ID: 23368510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.
    Henry RR; Mudaliar S; Kanitra L; Woloschak M; Balena R;
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2370-9. PubMed ID: 22539590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
    Riddle MC; Forst T; Aronson R; Sauque-Reyna L; Souhami E; Silvestre L; Ping L; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2497-503. PubMed ID: 23564915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.
    Seino Y; Takami A; Boka G; Niemoeller E; Raccah D;
    Diabetes Obes Metab; 2014 Aug; 16(8):739-47. PubMed ID: 24524806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
    Rosenstock J; Hanefeld M; Shamanna P; Min KW; Boka G; Miossec P; Zhou T; Muehlen-Bartmer I; Ratner RE
    J Diabetes Complications; 2014; 28(3):386-92. PubMed ID: 24650952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
    Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
    Seino Y; Ikeda Y; Niemoeller E; Watanabe D; Takagi H; Yabe D; Inagaki N
    Horm Metab Res; 2015 Nov; 47(12):895-900. PubMed ID: 26039935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.